CAMKII HYPERACTIVATION IN SKELETAL MUSCLES IS A DRIVER AND POTENTIAL THERAPEUTIC TARGET OF SARCOPENIA
2024
CaMKII Hyperactivation and Sarcopenia
Sample size: 12
publication
Evidence: moderate
Author Information
Author(s): Wang Qinchuan, Bene Michael, Fountain William, Rosales-Soto Giovanni, Hernandez-Ochoa Erick, Chung Tae Hwan, Walston Jeremy
Primary Institution: Johns Hopkins University School of Medicine
Hypothesis
Is CaMKII hyperactivation a driver of sarcopenia and a potential therapeutic target?
Conclusion
CaMKII hyperactivation is linked to sarcopenia and may be a target for treatment.
Supporting Evidence
- Old mice showed significantly increased CaMKII activity at rest.
- Inhibiting CaMKII improved muscle contractile force in older mice.
- Activating CaMKII in young mice reduced muscle contractility.
Takeaway
As we get older, a protein called CaMKII becomes too active in our muscles, which can make them weaker, but we might be able to fix this.
Methodology
The study assessed CaMKII activity in young and old mice and used viral vectors to manipulate CaMKII levels in muscle.
Participant Demographics
C57BL/6J mice, both young (4 months) and old (20 months).
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website